Eagle Global Advisors LLC Has $281,000 Stock Position in Pfizer Inc. (NYSE:PFE)

Eagle Global Advisors LLC decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 16.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,748 shares of the biopharmaceutical company’s stock after selling 1,905 shares during the period. Eagle Global Advisors LLC’s holdings in Pfizer were worth $281,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in PFE. Congress Wealth Management LLC DE lifted its position in Pfizer by 48.7% during the 4th quarter. Congress Wealth Management LLC DE now owns 60,134 shares of the biopharmaceutical company’s stock valued at $1,731,000 after purchasing an additional 19,687 shares during the period. Advisory Services Network LLC lifted its position in Pfizer by 8.7% during the 4th quarter. Advisory Services Network LLC now owns 442,267 shares of the biopharmaceutical company’s stock valued at $12,733,000 after purchasing an additional 35,337 shares during the period. Team Hewins LLC acquired a new position in Pfizer during the 4th quarter valued at about $1,093,000. TCW Group Inc. lifted its position in Pfizer by 82.7% during the 4th quarter. TCW Group Inc. now owns 205,376 shares of the biopharmaceutical company’s stock valued at $5,913,000 after purchasing an additional 92,970 shares during the period. Finally, SageView Advisory Group LLC lifted its position in Pfizer by 2.2% during the 4th quarter. SageView Advisory Group LLC now owns 45,186 shares of the biopharmaceutical company’s stock valued at $1,221,000 after purchasing an additional 973 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on PFE shares. Morgan Stanley upped their target price on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 price target (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Guggenheim assumed coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. Ten investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $35.86.

Pfizer Stock Up 0.7 %

NYSE PFE traded up $0.19 during trading hours on Friday, reaching $28.88. 22,589,127 shares of the company’s stock were exchanged, compared to its average volume of 44,974,800. The company has a market capitalization of $163.65 billion, a price-to-earnings ratio of -481.25, a price-to-earnings-growth ratio of 1.13 and a beta of 0.63. Pfizer Inc. has a one year low of $25.20 and a one year high of $40.37. The company’s 50-day moving average is $27.27 and its two-hundred day moving average is $27.96. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.26. The company had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business’s quarterly revenue was down 19.5% on a year-over-year basis. During the same period last year, the business earned $1.23 EPS. On average, analysts forecast that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 5.82%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s payout ratio is presently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.